News | August 02, 2024
Dabur Q1 FY25 consolidated net profit up 8% at Rs 500 Cr
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
Report highlights significant improvements in adolescent well-being in India
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Subscribe To Our Newsletter & Stay Updated
